Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04244812
Other study ID # 2019ZY008-MERIDIAN
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2020
Est. completion date December 31, 2021

Study information

Verified date January 2020
Source Zhejiang Chinese Medical University
Contact Yongliang Jiang, M.D
Phone 86-13858173136
Email jyl2182@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to detect the microcirculatory characteristics of meridian phenomena by using an objective assessment tool and investigate the site specificity for the meridian-visceral association and surface-surface association between two specific meridians.


Description:

The Lung and Heart meridians are chosen as two specific studied meridians. Participants of chronic stable angina pectoris (CSAP) and healthy volunteers will be enrolled.

120 participants will be included and divided into the healthy control group, chronic stable angina pectoris (CSAP) group and healthy intervention group. Laser doppler flowmetry (LDF) will be used to assess the microcirculatory characteristics of meridian phenomena for the Heart and Lung meridians. The site specificity for the meridian-visceral association will be investigated by comparing the microcirculatory difference between the Heart and Lung meridians in the healthy control group and CSAP group. Besides, participants in the healthy intervention group will receive two sessions of moxibustion in the Heart meridian and Lung meridian respectively to explore the site specificity for the surface-surface association.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date December 31, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

Inclusion criteria for the CSAP group

- Patients should meet the diagnostic criteria of coronary heart disease, which includes the following items: 1)confirmed old myocardial infarction (MI), or a history of percutaneous coronary intervention(PCI), or coronary artery bypass grafting; 2)50% or more luminal stenosis in at least one coronary artery or major branch segment confirmed by coronary angiogram or CT angiography; 3) myocardial ischemia indicted by exercise stress radionuclide myocardial imaging; 4) treadmill exercise testing is positive (for male patients);

- Patients should meet the diagnostic criteria of CSAP and the Canadian Cardiovascular Society(CCS) classification for CSAP is level II or III;

- The medical history of CSAP is more than 3 months with attacks occurring at least twice weekly in the last month;

- 35 = age =75 years, male or female;

- Patients have clear consciousness and could communicate with others normally;

- Patients could understand the full study protocol and written informed consent is signed.

Inclusion criteria for health volunteers

- Healthy volunteers should provide a recent medical examination report to confirm they have not any cardiovascular, respiratory, digestive, urinary, hematological, endocrine and neurological disease;

- age=20 years, male or female;

- Participants have clear consciousness and could communicate with others normally;

- Participants could understand the full study protocol and written informed consent is provided by themselves or their lineal kin.

Exclusion Criteria:

Exclusion criteria for the CSAP group

- Patients with acute coronary syndrome and severe arrhythmias;

- Patients'chest pain is caused by valvular heart disease, hypertrophic cardiomyopathy and dilated cardiomyopathy;

- Patients'chest pain is caused by non-cardiac disease;

- Patients have concomitant conditions of lung diseases, such as obstructive pulmonary disease;

- Patients have serious concomitant conditions and fail to treat them effectively, such as diseases of the digestive, urinary, respiratory, hematological and nervous system;

- Patients have mental illness, severe depression, alcohol dependence or history of drug abuse;

- Pregnant or lactating patients;

- Patients are participating in other trials.

Exclusion criteria for health volunteers

- Participants have mental illness, severe depression, alcohol dependence or history of drug abuse;

- Pregnant or lactating participants ;

- Participants are participating in other trials.

Study Design


Intervention

Other:
Moxibustion
Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively. Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm. Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm.
Device:
Laser doppler flowmetry
Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena

Locations

Country Name City State
China the Third affiliated hospital of Zhejiang Chinese Medical university Hanzhou Zhejiang

Sponsors (3)

Lead Sponsor Collaborator
Zhejiang Chinese Medical University The First Affiliated Hospital of Zhejiang Chinese Medical University, The Third Affiliated hospital of Zhejiang Chinese Medical University

Country where clinical trial is conducted

China, 

References & Publications (4)

Hsiu H, Hsu WC, Hsu CL, Huang SM, Jan MY, Wang WK, Wang YY. Spectral analysis on the microcirculatory laser Doppler signal at the acupuncture point. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:1084-6. doi: 10.1109/IEMBS.2008.4649348. — View Citation

Hsiu H, Hsu WC, Huang SM, Hsu CL, Lin Wang YY. Spectral analysis of the microcirculatory laser Doppler signal at the Hoku acupuncture point. Lasers Med Sci. 2009 May;24(3):353-8. doi: 10.1007/s10103-008-0569-8. Epub 2008 May 27. — View Citation

Hsiu H, Hsu WC, Wu YF, Hsu CL, Chen CY. Differences in the skin-surface laser Doppler signals between polycystic ovary syndrome and normal subjects. Microcirculation. 2014 Feb;21(2):124-30. doi: 10.1111/micc.12095. — View Citation

Hsiu H, Huang SM, Chao PT, Jan MY, Hsu TL, Wang WK, Wang YY. Microcirculatory characteristics of acupuncture points obtained by laser Doppler flowmetry. Physiol Meas. 2007 Oct;28(10):N77-86. Epub 2007 Sep 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline blood flow curve Laser doppler flowmetry is used to assess blood flow curve of relevant sites along the Heart and Lung meridians 5-minute baseline, 15 minutes during moxibustion and 5 minutes after stopping moxibustion
Primary Change from baseline blood perfusion units Laser doppler flowmetry is used to assess blood perfusion units of relevant sites along the Heart and Lung meridians 5-minute baseline, 15 minutes during moxibustion and 5 minutes after stopping moxibustion
See also
  Status Clinical Trial Phase
Recruiting NCT03914131 - Clinical Trial Scheme of Xinnaoning Capsule Phase 4
Not yet recruiting NCT04264559 - The Heat Transport Characteristics of the Heart and Lung Meridians: A Study of CSAP Patients and Healthy Adults N/A
Recruiting NCT04041206 - A Study on the Microcirculatory Characteristics of Meridian Phenomenon for the Heart and Lung Meridians Based on Patients With Stable Angina Pectoris
Recruiting NCT04041245 - A Study on the Metabolic Characteristics of Meridian Phenomenon for the Heart and Lung Meridians Based on Patients With Stable Angina Pectoris
Recruiting NCT03789552 - Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina Phase 3
Completed NCT02315976 - Acute Episodes in Chronic Stable Angina: Assessment of the Use of the Coronary Vasodilator Propatyl Nitrate. Phase 4